Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS‐010759
Sign Up to like & getrecommendations! Published in 2024 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13583
Abstract: Metformin and IACS‐010759 are two distinct antimetabolic agents. Metformin, an established antidiabetic drug, mildly inhibits mitochondrial complex I, while IACS‐010759 is a new potent mitochondrial complex I inhibitor. Mitochondria is pivotal in the energy metabolism… read more here.
Keywords: cancer immune; metabolism; metformin iacs; targeting cancer ... See more keywords
Immune Cycle‐Based Strategies for Cancer Immunotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Advanced Functional Materials"
DOI: 10.1002/adfm.202107540
Abstract: The immune system is composed of immune organs, immune cells, and immunoactive substances, which plays a vital role in antitumor immunity in cancer immunotherapy. During the process of the antitumor immune response, many factors are… read more here.
Keywords: cancer; cancer immune; immune cycle; cancer immunotherapy ... See more keywords
Complex interactions between the microbiome and cancer immune therapy
Sign Up to like & getrecommendations! Published in 2019 at "Critical Reviews in Clinical Laboratory Sciences"
DOI: 10.1080/10408363.2019.1660303
Abstract: Abstract Immuno-oncology has rapidly grown in the last thirty years, and immunotherapeutic agents are now approved to treat many disparate cancers. Immune checkpoint inhibitors (ICIs) are employed to augment cytotoxic anti-cancer activity by inhibiting negative… read more here.
Keywords: cancer immune; therapy; immune therapy; colitis ... See more keywords
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort
Sign Up to like & getrecommendations! Published in 2019 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1483303
Abstract: ABSTRACT Determining prostate cancer (PCa) aggressiveness and reclassification are critical events during the treatment of localized disease and for patients undergoing active surveillance (AS). Since T cells play major roles in cancer surveillance and elimination,… read more here.
Keywords: cell cancer; immune response; surveillance; cancer ... See more keywords
Immune sunrise: from the immunome to the cancer immune landscape
Sign Up to like & getrecommendations! Published in 2022 at "Oncoimmunology"
DOI: 10.1080/2162402x.2021.2019896
Abstract: ABSTRACT The complex dynamics of the tumor-immune interaction during tumor progression have been characterized by integrating genomic and proteomic experiments. The Immunome, a reference compendium of markers for the majority of immune cell subpopulations was… read more here.
Keywords: immune sunrise; sunrise immunome; cancer; immune landscape ... See more keywords
Allergen immunotherapy, cancer, and immune disorders
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Allergy and Clinical Immunology"
DOI: 10.1097/aci.0000000000000858
Abstract: Purpose of review The purpose of this review is to provide an update on the intriguing relationships between allergies, allergen immunotherapy, cancer, and immune disorders. Allergic diseases and cancer are increasing in incidence and prevalence… read more here.
Keywords: immunotherapy cancer; cancer immune; immune disorders; allergen immunotherapy ... See more keywords
PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Sign Up to like & getrecommendations! Published in 2023 at "Science Advances"
DOI: 10.1126/sciadv.ade4186
Abstract: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) have enabled some patients with cancer to experience durable, complete treatment responses; however, reliable anti–PD-(L)1 treatment response… read more here.
Keywords: methylation; k162 methylation; cancer immune; immune surveillance ... See more keywords
Abstract 4755: Role of PAK4 in cancer immune cell exclusion
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4755
Abstract: Lack of T-cell infiltration is the main mechanism of primary resistance to checkpoint blockade therapies. Here, we performed a transcriptomic analysis of metastatic melanoma biopsies taken from patients treated with anti-PD1 (n=23) with biopsies pre-… read more here.
Keywords: cancer immune; immune cell; pak4 cancer; role pak4 ... See more keywords
Abstract PL03-03: Taming the beast: Strategies to target the immune-suppressive macrophage to enhance cancer immune therapy
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-pl03-03
Abstract: Advances in basic, translational and clinical research have revealed the power of cancer immune therapy. Checkpoint inhibitors and adoptive T cell therapies are novel, FDA approved therapeutic strategies that promote recruitment to and activation of… read more here.
Keywords: therapy; immune suppressive; immune therapy; cancer ... See more keywords
Abstract 4178: Investigating glucose utilization in cancer and immune cells using bioluminescent metabolite and enzyme assays
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4178
Abstract: Glucose metabolism is fundamental to the function and survival of both cancer cells and immune cells within the tumor microenvironment. Cancer cells often exhibit altered metabolic pathways to meet the elevated energy and anabolic demands… read more here.
Keywords: cancer; immune cells; cancer immune; glycogen ... See more keywords
Abstract B02: Ephrin receptor A10 promotes PD-L1 expression for breast cancer immune evasion
Sign Up to like & getrecommendations! Published in 2020 at "Cancer immunology research"
DOI: 10.1158/2326-6074.tumimm18-b02
Abstract: Programmed death-ligand 1(PD-L1) is an immune checkpoint protein and its engagement with programmed cell death protein-1 (PD-1) receptor on T cells activates co-inhibitory signaling to induce cancer immune evasion. PD-L1 or PD-1 blockade has demonstrated… read more here.
Keywords: expression; cancer; receptor; breast cancer ... See more keywords